BGT226, with the CAS number 915020-55-2, is a chemical compound that has garnered attention in the field of medicinal chemistry, particularly for its potential therapeutic applications. It is classified as a small molecule inhibitor, specifically targeting certain kinases involved in various cellular processes, including cell proliferation and survival. The compound exhibits a unique structure that allows it to interact selectively with its biological targets, which may contribute to its efficacy in treating specific diseases, such as cancer. BGT226 has been studied for its pharmacological properties, including its ability to inhibit tumor growth in preclinical models. Additionally, its solubility, stability, and bioavailability are critical factors that influence its development as a therapeutic agent. As research continues, understanding the detailed mechanism of action, potential side effects, and optimal dosing regimens will be essential for evaluating its clinical utility. Overall, BGT226 represents a promising candidate in the ongoing search for effective treatments in oncology and related fields.

BGT226

915020-55-2: BGT226, with the CAS number 915020-55-2, is a chemical compound that has garnered attention in the field of medicinal chemistry, particularly for its potential therapeutic applications. It is classified as a small molecule inhibitor, specifically targeting certain kinases involved in various cellular processes, including cell proliferation and survival. The compound exhibits a unique structure that allows it to interact selectively with its biological targets, which may contribute to its efficacy in treating specific diseases, such as cancer. BGT226 has been studied for its pharmacological properties, including its ability to inhibit tumor growth in preclinical models. Additionally, its solubility, stability, and bioavailability are critical factors that influence its development as a therapeutic agent. As research continues, understanding the detailed mechanism of action, potential side effects, and optimal dosing regimens will be essential for evaluating its clinical utility. Overall, BGT226 represents a promising candidate in the ongoing search for effective treatments in oncology and related fields.

BGT226 (NVP-BGT226) is a novel dual PI3K / mTOR inhibitor, it acts on PI3K α/β/γ with IC50 of 4 nM / 63 nM / 38 nM, respectively.

CAS 915020-55-2

BGT226

BGT226

Ref: 54-BUP14302

BGT226

Ref: TM-T6072L